Loading...

Kiwa Bio-Tech Products Group

OTCPK:KWBT
Snowflake Description

Excellent balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
KWBT
OTCPK
$15M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Kiwa Bio-Tech Products Group Corporation, through its subsidiaries, develops, manufactures, distributes, and markets bio-technological products for the agricultural market primarily in the People’s Republic of China. The last earnings update was 6 days ago. More info.


Add to Portfolio Compare Print
  • Kiwa Bio-Tech Products Group has significant price volatility in the past 3 months.
KWBT Share Price and Events
7 Day Returns
-15.7%
OTCPK:KWBT
-3%
US Biotechs
0.8%
US Market
1 Year Returns
-31.8%
OTCPK:KWBT
-0.6%
US Biotechs
5.9%
US Market
KWBT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Kiwa Bio-Tech Products Group (KWBT) -15.7% -18.2% -9.1% -31.8% -51.9% 57.3%
US Biotechs -3% -4% 0.6% -0.6% 5.1% 17.3%
US Market 0.8% 2.6% 10.6% 5.9% 37.7% 45.5%
1 Year Return vs Industry and Market
  • KWBT underperformed the Biotechs industry which returned -0.6% over the past year.
  • KWBT underperformed the Market in United States of America which returned 5.9% over the past year.
Price Volatility
KWBT
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Kiwa Bio-Tech Products Group undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Kiwa Bio-Tech Products Group. This is due to cash flow or dividend data being unavailable. The share price is $0.818.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Kiwa Bio-Tech Products Group's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Kiwa Bio-Tech Products Group's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:KWBT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $0.02
OTCPK:KWBT Share Price ** OTCPK (2019-04-17) in USD $0.82
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 20.52x
United States of America Market PE Ratio Median Figure of 3,078 Publicly-Listed Companies 18.23x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Kiwa Bio-Tech Products Group.

OTCPK:KWBT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OTCPK:KWBT Share Price ÷ EPS (both in USD)

= 0.82 ÷ 0.02

39.31x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Kiwa Bio-Tech Products Group is overvalued based on earnings compared to the US Biotechs industry average.
  • Kiwa Bio-Tech Products Group is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does Kiwa Bio-Tech Products Group's expected growth come at a high price?
Raw Data
OTCPK:KWBT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 39.31x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
24.9%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 28 Publicly-Listed Biotechs Companies 1.73x
United States of America Market PEG Ratio Median Figure of 2,108 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Kiwa Bio-Tech Products Group, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Kiwa Bio-Tech Products Group's assets?
Raw Data
OTCPK:KWBT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.75
OTCPK:KWBT Share Price * OTCPK (2019-04-17) in USD $0.82
United States of America Biotechs Industry PB Ratio Median Figure of 412 Publicly-Listed Biotechs Companies 3.34x
United States of America Market PB Ratio Median Figure of 5,172 Publicly-Listed Companies 1.93x
OTCPK:KWBT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OTCPK:KWBT Share Price ÷ Book Value per Share (both in USD)

= 0.82 ÷ 0.75

1.09x

* Primary Listing of Kiwa Bio-Tech Products Group.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Kiwa Bio-Tech Products Group is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Kiwa Bio-Tech Products Group's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Kiwa Bio-Tech Products Group has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Kiwa Bio-Tech Products Group expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

  • No analysts cover Kiwa Bio-Tech Products Group, future earnings growth has been estimated based on fundamentals.
The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
24.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Kiwa Bio-Tech Products Group expected to grow at an attractive rate?
  • Kiwa Bio-Tech Products Group's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Kiwa Bio-Tech Products Group's earnings growth is expected to exceed the United States of America market average.
  • Unable to compare Kiwa Bio-Tech Products Group's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OTCPK:KWBT Future Growth Rates Data Sources
Data Point Source Value (per year)
OTCPK:KWBT Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts 24.9%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:KWBT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:KWBT Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 31 -2 0
2018-09-30 39 -4 3
2018-06-30 31 0 2
2018-03-31 26 -6 1
2017-12-31 17 -6 1
2017-09-30 8 -4 -1
2017-06-30 10 -3 -1
2017-03-31 10 -2 1
2016-12-31 10 -1 1
2016-09-30 1 -1 1
2016-06-30 0 0
2016-03-31 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Kiwa Bio-Tech Products Group's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Kiwa Bio-Tech Products Group is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:KWBT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Kiwa Bio-Tech Products Group Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:KWBT Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 0.02
2018-09-30 0.19
2018-06-30 0.11
2018-03-31 0.11
2017-12-31 0.08
2017-09-30 -0.15
2017-06-30 -0.06
2017-03-31 0.07
2016-12-31 0.20
2016-09-30 0.15
2016-06-30 -0.04
2016-03-31 -0.22

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Kiwa Bio-Tech Products Group will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Kiwa Bio-Tech Products Group's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Kiwa Bio-Tech Products Group has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Kiwa Bio-Tech Products Group performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Kiwa Bio-Tech Products Group's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Kiwa Bio-Tech Products Group's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
  • Kiwa Bio-Tech Products Group's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Kiwa Bio-Tech Products Group's 1-year earnings growth is negative, it can't be compared to the US Biotechs industry average.
Earnings and Revenue History
Kiwa Bio-Tech Products Group's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Kiwa Bio-Tech Products Group Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:KWBT Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 30.65 0.34 5.55 0.12
2018-09-30 39.05 2.86 5.45 0.32
2018-06-30 31.36 1.54 5.78 0.15
2018-03-31 26.03 1.34 4.80 0.15
2017-12-31 17.27 0.81 3.48 0.15
2017-09-30 8.47 -1.46 3.21 0.27
2017-06-30 9.62 -0.50 2.30 0.07
2017-03-31 9.62 0.51 1.74 0.11
2016-12-31 9.62 1.04 1.40 0.15
2016-09-30 1.19 0.54 0.38 0.01
2016-06-30 -0.12 0.39 0.25
2016-03-31 -0.46 0.32 0.22
2015-12-31 -0.43 0.22 0.02
2015-09-30 -0.74 0.33 0.16
2015-06-30 -0.73 0.34 0.16
2015-03-31 -0.72 0.36 0.16
2014-12-31 -0.71 0.36 0.16
2014-09-30 -0.60 0.32 0.16
2014-06-30 4.13 0.38 0.16
2014-03-31 3.92 0.39 0.16
2013-12-31 3.71 0.39 0.16
2013-09-30 3.48 0.02 0.16
2013-06-30 -1.47 0.13 0.16
2013-03-31 -1.46 0.28 0.16
2012-12-31 -1.46 0.44 0.16
2012-09-30 -1.47 1.05 0.17
2012-06-30 -1.46 1.03 0.17

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Kiwa Bio-Tech Products Group has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Kiwa Bio-Tech Products Group used its assets less efficiently than the US Biotechs industry average last year based on Return on Assets.
  • Unable to establish if Kiwa Bio-Tech Products Group improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to insufficient past data.
X
Past performance checks
We assess Kiwa Bio-Tech Products Group's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Kiwa Bio-Tech Products Group has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Kiwa Bio-Tech Products Group's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Kiwa Bio-Tech Products Group's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Kiwa Bio-Tech Products Group is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Kiwa Bio-Tech Products Group has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Kiwa Bio-Tech Products Group's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 23.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Kiwa Bio-Tech Products Group Company Filings, last reported 3 months ago.

OTCPK:KWBT Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 12.73 1.33 0.01
2018-09-30 12.51 1.24 0.01
2018-06-30 12.07 1.21 5.08
2018-03-31 12.98 1.20 0.06
2017-12-31 10.67 1.09 1.08
2017-09-30 1.85 1.02 0.02
2017-06-30 1.73 1.55 0.07
2017-03-31 -4.15 2.40 0.14
2016-12-31 -4.24 0.51 0.01
2016-09-30 -5.02 2.23 0.00
2016-06-30 -7.45 2.24 0.01
2016-03-31 -7.94 2.29 0.04
2015-12-31 -11.10 3.39 0.03
2015-09-30 -10.94 1.96 0.02
2015-06-30 -11.13 2.03 0.02
2015-03-31 -10.98 2.03 0.02
2014-12-31 -11.85 5.94 0.02
2014-09-30 -10.65 2.02 0.02
2014-06-30 -10.42 2.00 0.03
2014-03-31 -10.25 2.00 0.02
2013-12-31 -10.31 2.05 0.02
2013-09-30 -10.06 2.03 0.02
2013-06-30 -14.63 3.50 0.02
2013-03-31 -14.18 3.48 0.10
2012-12-31 -13.81 3.48 0.03
2012-09-30 -13.35 3.46 0.04
2012-06-30 -13.02 3.44 0.03
  • Kiwa Bio-Tech Products Group's level of debt (10.5%) compared to net worth is satisfactory (less than 40%).
  • Kiwa Bio-Tech Products Group had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
  • Operating cash flow is negative therefore debt is not well covered.
  • Interest payments on debt are well covered by earnings (EBIT is 4.1x coverage).
X
Financial health checks
We assess Kiwa Bio-Tech Products Group's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Kiwa Bio-Tech Products Group has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Kiwa Bio-Tech Products Group's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Kiwa Bio-Tech Products Group dividends.
If you bought $2,000 of Kiwa Bio-Tech Products Group shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Kiwa Bio-Tech Products Group's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Kiwa Bio-Tech Products Group's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:KWBT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 20 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2009 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Kiwa Bio-Tech Products Group has not reported any payouts.
  • Unable to verify if Kiwa Bio-Tech Products Group's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Kiwa Bio-Tech Products Group's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Kiwa Bio-Tech Products Group has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Kiwa Bio-Tech Products Group's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Kiwa Bio-Tech Products Group afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Kiwa Bio-Tech Products Group has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Kiwa Bio-Tech Products Group's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Yvonne Wang-Liu
COMPENSATION $84,000
AGE 40
TENURE AS CEO 2.7 years
CEO Bio

Ms. Siuhung Wang-Liu, also known as Yvonne has been an Acting Chief Executive Officer and Acting President of Kiwa Bio-Tech Products Group Corporation since August 11, 2016. Ms. Wang-Liu has been the Chairman of Kiwa Bio-Tech Products Group Corporation since November 20, 2015 and served as its Chief Operating Officer since December 15, 2015 and served as its Company Secretary since September 2005 until November 20, 2015. She served as Acting Chief Financial Officer of Kiwa Bio-Tech Products Group Corporation since August 11, 2016 to April 17, 2018. Ms. Wang-Liu served as the Chief Financial Officer and Chief Operating Officer of Xinhua Finance Limited and was responsible for developing its overall financial strategy and internal control. She has over 17 years of solid experience from Big 6 accounting firms. Prior to joining Xinhua Finance, Ms. Wang-Liu worked at Xinhua Finance Limited's subsidiary Xinhua Sports & Entertainment Limited as the Vice-President of Finance, where she led the finance team to successfully obtain Sarbanes Oxley Compliance and a series of campaigns to improve financial control. She served as an Assistant of Executive and Manager of Kiwa's US office since April 2003 until September 2005. She is also a Realtor and committees in California and a Certified Notary Public from California's Secretary of State. She has been a Director of Kiwa Bio-Tech Products Group Corporation since October 12, 2015. She serves as a Director of Xinhua Holdings Limited. Ms. Wang-Liu holds a B.S. degree of Business Administration in July 2001, from University of Phoenix and an Master of Business Administration (MBA) from University of Southern California and she is a Certified Public Accountant (CPA).

CEO Compensation
  • Yvonne's compensation has been consistent with company performance over the past year.
  • Yvonne's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Kiwa Bio-Tech Products Group management team in years:

2.8
Average Tenure
44.5
Average Age
  • The tenure for the Kiwa Bio-Tech Products Group management team is about average.
Management Team

Yvonne Wang-Liu

TITLE
Chairman
COMPENSATION
$84K
AGE
40
TENURE
2.7 yrs

Xiao Qiang Yu

TITLE
Chief Operating Officer
COMPENSATION
$60K
AGE
40
TENURE
2.8 yrs

Yong Lin Song

TITLE
CTO, Director of Technology & Director
COMPENSATION
$62K
AGE
51
TENURE
3.1 yrs

Hon Man Yun

TITLE
Chief Financial Officer
AGE
49
TENURE
1 yrs

Qi Wang

TITLE
VP of Technology & Director
AGE
52

Lucy Li

TITLE
Secretary & Director
AGE
30
TENURE
4.3 yrs
Board of Directors Tenure

Average tenure and age of the Kiwa Bio-Tech Products Group board of directors in years:

3.8
Average Tenure
45.5
Average Age
  • The tenure for the Kiwa Bio-Tech Products Group board of directors is about average.
Board of Directors

Yvonne Wang-Liu

TITLE
Chairman
COMPENSATION
$84K
AGE
40
TENURE
3.4 yrs

Yong Lin Song

TITLE
CTO, Director of Technology & Director
COMPENSATION
$62K
AGE
51
TENURE
2.1 yrs

Qi Wang

TITLE
VP of Technology & Director
AGE
52
TENURE
11.8 yrs

Lucy Li

TITLE
Secretary & Director
AGE
30
TENURE
4.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Kiwa Bio-Tech Products Group's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Kiwa Bio-Tech Products Group has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Kiwa Bio-Tech Products Group Corporation, through its subsidiaries, develops, manufactures, distributes, and markets bio-technological products for the agricultural market primarily in the People’s Republic of China. It offers bacillus species and/or photosynthetic bacteria based biological organic and compound microbial fertilizers. The company has a strategic relationship with ETS (Tianjin) Biological Science and Technology Development Co., Ltd. to produce bio-fertilizers in the People’s Republic of China and internationally; and strategic cooperation agreements with the Beijing Zhongpin Agricultural Science and Technology Development Center, as well as China Academy of Agricultural Science’s Institute of Agricultural Resources & Regional Planning, and Institute of Agricultural Economy & Development. Kiwa Bio-Tech Products Group Corporation was founded in 2002 and is headquartered in Yangling, China.

Details
Name: Kiwa Bio-Tech Products Group Corporation
KWBT
Exchange: OTCPK
Founded: 2002
$15,426,430
18,858,717
Website: http://www.kiwabiotech.com
Address: Kiwa Bio-Tech Products Group Corporation
International Agriculture Innovation Hub,
9th Floor,
Yangling,
Shaanxi Province, 712100,
China
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK KWBT Common Stock Pink Sheets LLC US USD 15. Mar 2004
Number of employees
Current staff
Staff numbers
82
Kiwa Bio-Tech Products Group employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 23:52
End of day share price update: 2019/04/17 00:00
Last earnings filing: 2019/04/12
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.